+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Cinryze"

Global Angioedema Treatment Market by Drugs Type (C1 Esterase Inhibitor, Kallikrein Inhibitor, Selective Bradykinin B2 Receptor Antagonist), Route of Administration (Injections, Oral), End-User - Forecast 2024-2030 - Product Thumbnail Image

Global Angioedema Treatment Market by Drugs Type (C1 Esterase Inhibitor, Kallikrein Inhibitor, Selective Bradykinin B2 Receptor Antagonist), Route of Administration (Injections, Oral), End-User - Forecast 2024-2030

  • Report
  • March 2024
  • 183 Pages
  • Global
From
Hereditary Angioedema Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 to 2030 - Product Thumbnail Image

Hereditary Angioedema Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 to 2030

  • Report
  • August 2022
  • 120 Pages
  • Global
From
Cinryze C1- Drug Insight, 2019 - Product Thumbnail Image

Cinryze C1- Drug Insight, 2019

  • Drug Pipelines
  • January 2019
  • 35 Pages
  • Global
From
  • 3 Results (Page 1 of 1)
Loading Indicator

Cinryze is a brand of immune disorder drugs used to treat hereditary angioedema (HAE). It is a rare, genetic disorder that causes episodes of swelling in the face, extremities, gastrointestinal tract, and airway. Cinryze is a C1 esterase inhibitor (C1-INH) that works by replacing the missing or deficient C1-INH protein in the body. It is administered intravenously and is used to prevent and treat HAE attacks. Cinryze is the only FDA-approved C1-INH therapy for HAE and is the only therapy approved for routine prophylaxis. The Cinryze market is composed of a variety of companies that produce and distribute C1-INH therapies. These companies include Shire, CSL Behring, Pharming Group, and ViroPharma. Additionally, there are several generic versions of C1-INH therapies available in the market. Show Less Read more